Scholarlink

<p>Corneal epithelial defects and dry eye disease are leading causes of ocular morbidity, characterized by epithelial damage, inflammation, and tear film instability that current monotherapies rarely address simultaneously. Polydeoxyribonucleotide (PDRN) promotes tissue regeneration and suppresses inflammation, while 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) reduces tear evaporation. We evaluated a contact lens co-delivering PDRN and DMPC (PDRN+DMPC) in two rabbit models: a corneal epithelial wound healing model and a meibomian gland dysfunction–induced dry eye model. In each animal, one eye received a control lens and the contralateral eye a PDRN+DMPC lens worn six hours daily. Outcomes included epithelial defect area, tear break-up time, histology, and gene expression. In the wound model, the PDRN+DMPC lens accelerated re-epithelialization and produced greater epithelial thickness. In the dry eye model, tear break-up time was prolonged, tear osmolarity reduced, and epithelial desquamation decreased. Pro-inflammatory cytokines were selectively suppressed, and membrane-associated mucins (MUC1 and MUC16) were downregulated, whereas the secreted gel-forming mucin MUC5AC, goblet cells, epithelial differentiation markers, and tight junction genes were preserved. Thus, the PDRN+DMPC lens accelerates corneal wound healing, restores tear film homeostasis, and limits inflammation while maintaining protective mucin and barrier components, supporting its potential as a multifunctional therapeutic platform for ocular surface disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A contact lens delivering a combination of PDRN and DMPC enhances corneal wound healing and alleviates dry eye in a rabbit model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月31日

查看全文
  • Hye-Jin Son,
  • Se Hyun Choi,
  • Sooyoung Choe,
  • Mi Youn Seol,
  • Yunkyoung Ryu,
  • Jae Hwi Lee,
  • Gui Bae Kim,
  • Young Joo Shin

摘要

Corneal epithelial defects and dry eye disease are leading causes of ocular morbidity, characterized by epithelial damage, inflammation, and tear film instability that current monotherapies rarely address simultaneously. Polydeoxyribonucleotide (PDRN) promotes tissue regeneration and suppresses inflammation, while 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) reduces tear evaporation. We evaluated a contact lens co-delivering PDRN and DMPC (PDRN+DMPC) in two rabbit models: a corneal epithelial wound healing model and a meibomian gland dysfunction–induced dry eye model. In each animal, one eye received a control lens and the contralateral eye a PDRN+DMPC lens worn six hours daily. Outcomes included epithelial defect area, tear break-up time, histology, and gene expression. In the wound model, the PDRN+DMPC lens accelerated re-epithelialization and produced greater epithelial thickness. In the dry eye model, tear break-up time was prolonged, tear osmolarity reduced, and epithelial desquamation decreased. Pro-inflammatory cytokines were selectively suppressed, and membrane-associated mucins (MUC1 and MUC16) were downregulated, whereas the secreted gel-forming mucin MUC5AC, goblet cells, epithelial differentiation markers, and tight junction genes were preserved. Thus, the PDRN+DMPC lens accelerates corneal wound healing, restores tear film homeostasis, and limits inflammation while maintaining protective mucin and barrier components, supporting its potential as a multifunctional therapeutic platform for ocular surface disease.